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What is already known on this topic?
 Ź There is evidence that incentive-based 
breastfeeding programmes can increase breast 
feeding in areas with low rates.
 Ź Solid evidence of the value for money of these 
programmes is lacking despite calls for such 
evidence.
What this study adds?
 Ź This study reports, for the irst time, cost-
effectiveness estimates of the offer of a 
inancial incentive for breast feeding in areas 
with low breastfeeding rates.
 Ź This study provides new and high-quality data 
from a large cluster randomised controlled trial 
(with 92% follow-up data), with resource use 
data collected prospectively.
 Ź Our study shows that these programmes can 
increase breast feeding and provide good value 
for money if decision makers are willing to pay 
£974 (or more) per additional baby receiving 
breastmilk.
ABSTRACT
Objective To provide the irst estimate of the cost-
effectiveness of inancial incentive for breastfeeding 
intervention compared with usual care.
Design Within-cluster (’ward’-level) randomised 
controlled trial cost-effectiveness analysis (trial 
registration number ISRCTN44898617).
Setting Five local authority districts in the North of 
England.
Participants 5398 mother-infant dyads (intervention 
arm), 4612 mother-infant dyads (control arm).
Interventions Offering a inancial incentive (over a 
6-month period) on breast feeding to women living 
in areas with low breastfeeding prevalence (<40% at 
6–8 weeks).
Main outcome measures Babies breast fed (receiving 
breastmilk) at 6–8 weeks, and cost per additional baby 
breast fed.
Methods Costs were compared with differences in 
area-level data on babies’ breast fed in order to estimate 
a cost per additional baby breast fed and the quality-
adjusted life year (QALY) gains required over the lifetime 
of babies to justify intervention cost.
Results In the trial, the total cost of providing the 
intervention in 46 wards was £462 600, with an 
average cost per ward of £9989 and per baby of £91. 
At follow-up, area-level breastfeeding prevalence at 
6–8 weeks was 31.7% (95% CI 29.4 to 34.0) in control 
areas and 37.9% (95% CI 35.0 to 40.8) in intervention 
areas. The adjusted difference between intervention 
and control was 5.7 percentage points (95% CI 2.7 to 
8.6; p<0.001), resulting in 10 (95% CI 6 to 14) more 
additional babies breast fed in the intervention wards 
(39 vs 29). The cost per additional baby breast fed at 
6–8 weeks was £974. At a cost per QALY threshold 
of £20 000 (recommended in England), an additional 
breastfed baby would need to show a QALY gain of 
0.05 over their lifetime to justify the intervention cost. 
If decision makers are willing to pay £974 (or more) per 
additional baby breast fed at a QALY gain of 0.05, then 
this intervention could be cost-effective. Results were 
robust to sensitivity analyses.
Conclusion This study provides information to help 
inform public health guidance on breast feeding. To 
make the economic case unequivocal, evidence on the 
varied and long-term health beneits of breast feeding 
to both the baby and mother and the effectiveness of 
inancial incentives for breastfeeding beyond 6–8 weeks 
is required.
INTRODUCTION
Breast feeding has benefits for both mothers and 
babies.1 However, rates of any (ie, exclusive and 
mixed) breast feeding at age 12 months, are below 
20%, on average, in high-income countries. The UK 
has the lowest rate (0.5%), Oman the highest (95%) 
and the USA has a rate of 27%.2 Even in low-in-
come and middle-income countries with relatively 
higher breastfeeding rates at age 12 months, only 4 
out of 10 babies younger than 6 months are exclu-
sively breast fed.2 The low prevalence of breast 
feeding is estimated to cost high-income countries 
US$231 billion (0.5% of gross national income) 
annually.1 Policy makers in high-income countries 
are seeking effective and cost-effective interven-
tions to encourage breastfeeding.3
Offering incentives to women to breast feed 
have been identified as an effective intervention to 
increase breast feeding and have been implemented 
in the USA,4 France5 and Canada.6 The first ever 
randomised controlled trial (RCT) of a financial 
incentive for breast feeding was conducted among 
36 low-income Puerto Rican mothers who had 
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initiated breast feeding. This US-based RCT found higher rates 
of continued breast feeding in the intervention group compared 
with control (89% vs 44% at 1 month; 89% vs 17%, at 3 
months; 72% vs 0%, at 6 months).4 The authors recommended 
large-scale studies to assess clinical and cost-effectiveness of 
incentive-based breastfeeding interventions.
The first UK-based RCT of financial incentives for breast 
feeding was conducted as part of the Nourishing Start for Health 
(NOSH) project.7 This project developed and then trialled a 
structured population-level financial incentive for breastfeeding 
intervention that offered shopping vouchers to women if their 
infant was receiving breastmilk. The intervention was offered 
to all women living in areas with low breastfeeding prevalence 
(<40% at 68 weeks) in five local authority districts in the 
North of England. Up to five vouchers (£40 each) were offered 
to women if their baby was receiving breastmilk at the following 
ages: 2 days, 10 days, 6 weeks, 3 months and 6 months.
To date, no cost-effectiveness studies of financial incentives 
for breast feeding have been identified.8 However, review of 
breastfeeding incentive programmes by Moran et al3 found eight 
studies with implementation costs data (but no cost-effective-
ness estimates). To ensure the efficient allocation of resources in 
health systems, global and national public health decision makers 
need information on the value for money of these interven-
tions. The WHO Breastfeeding Policy Brief9 identifies the need 
to increase attention to, investment in and action for a set of 
cost-effective interventions and policies, that can help Member 
States and their partners to increase breast feeding and reach 
the WHO Global 2025 breastfeeding target of at least 50% of all 
infants being exclusively breastfed in the first 6 months.
This study, to the best of our knowledge examines, for the 
first time, the cost-effectiveness of offering an area-level finan-
cial incentive for breastfeeding intervention in a general popu-
lation. Conducted alongside a large cluster (ward) RCT (trial 
registration number ISRCTN44898617), the analyses examined 
the within-trial cost-effectiveness of financial incentive for breast 
feeding in areas with low breastfeeding rates in the UK.
METHODS
The within-trial cost-effectiveness analysis compared the cost 
and benefits (in terms of babies receiving breastmilk) of offering 
financial incentives to women over a 6-month period postbirth 
versus control (no offer), from a healthcare provider perspective. 
The health outcome of interest was babies breast fed at 68 weeks 
and cost-effectiveness was reported as cost per additional baby 
breast fed over the four quarters of the 1-year trial. While data 
unavailability precluded estimating effectiveness at 6 months, 
total costs of vouchers were included in the analysis because the 
offer of vouchers up to 6 months was provided to participants at 
the outset of the trial and could therefore had impacted on the 
take up and duration of breast feeding. The protocol planned 
cost-effectiveness analysis10 was published prior to the analysis. 
The Trial Steering Committee approved changes from protocol 
to analyses. Changes were necessary because logistical and data 
constraints precluded: (a) the collection of area-level data on 
hospital admissions (related to gastrointestinal infection, otitis 
media, respiratory tract infections and atopic eczema) and (b) 
beyond trial modelling of the long-term cost-effectiveness of the 
intervention.
The total costs of providing the intervention in the trial 
included set up (website development, design and planning, 
booklet production, procurement, initial local engagement 
and staff induction) and delivery costs (including vouchers, 
processing of claims). Resource use data were extracted from 
trial management records, computer-based diaries and inter-
views with the trial manager. Resources were valued using 
national tariffs11 to increase generalisability. The unit costs of 
the vouchers were obtained from administrative records. Costs 
are expressed in pound sterling (201516), using the Hospital & 
Community Health Service inflation index where appropriate.11 
As the trial was within 1 year, a discount rate was not applied.
Multivariable regression models adjusting for baseline vari-
ables and potential imbalances in treatment group were used 
to generate the incremental cost-effectiveness estimates.12 A 
generalised linear model using Poisson distributional family (and 
robust SEs) was fitted to generate the cost per ward/trial arm and 
incremental cost per ward. As the control areas had zero cost, a 
constant value of £0.001 was added to observations for model 
convergence. Cost per baby/trial arm was derived by dividing 
the estimated mean cost per ward by the number of babies per 
ward. A negative binomial model was used to estimate the inter-
vention effect following the study by Relton et al,7 although with 
different estimator. The outcome used in the study by Relton et 
al,7 percentage point increase in breastfeeding outcome, is a rela-
tive measure and not applicable to cost-effectiveness analysis.
To provide estimates of uncertainty, the margins method 
generated sample means, by trial arm, for costs and breast 
feeding.12 The choice of distributional family for models was 
based on modified Park test12 and comparison of observed 
and predicted values. The covariates of the models included 
correlates of breastfeeding-related outcomes7 13 14: depriva-
tion (Index Multiple Deprivation) score for the wards, baseline 
breastfeeding rate and ethnicity, and the inverse of the variance 
of breastfeeding rate (to account for the number of births in rela-
tion to breast feeding). The choice of covariates was based on a 
literature review conducted as part of this study to identify the 
potential predictors of breastfeeding-related outcomes.
Results are reported as cost per additional baby breast fed at 
68 weeks. Deterministic sensitivity analyses assessed different 
components of total cost: (a) cost of routinely rolling out the 
scheme (covering induction and delivery costs) and (b) exclu-
sion of the cost of voucherthis was to demonstrate the impact 
of assuming cost of vouchers is a transfer payment (ie, giving 
women vouchers without any service in exchange); and there-
fore not includable in an economic evaluation. Probabilistic 
sensitivity analysis estimated the precision of the estimates of 
cost and breast feeding and investigated the robustness of poten-
tial differences in each. Bootstrap techniques (n=2000) based 
on regression models for costs and breastfeeding rates were 
employed to generate a sample of incremental costs and effects 
from an empirical distribution. This provided a measure of the 
probability that the intervention is cost-effective, at varying will-
ingness to pay (WTP) values for changes in breastfeeding.
RESULTS
Within-trial cost-effectiveness
Table 1 shows the descriptive statistics (unadjusted estimates). 
The total cost of providing the intervention in 46 wards, over 
12 months and 5398 births in the period, was £462 600 with 
an average cost per ward of £9989 (SD £5538) and per baby of 
£91 (SD £22.40). Delivery costs constituted 86%, followed by 
recruitment (8%), set up (5%) and training (1%). The highest 
individual contributors were vouchers (74%; £342 840) and 
initial local engagement costs (4%; £19 598). Total cost per 
ward ranged from £2523 to £31 255 (online supplementary 
1ac). The control wards had no cost.
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Table 1 Average costs of intervention arm (pound sterling  
2015–16)
Activities Activities
Average cost per 
ward (SD) n=46
Average cost per 
baby (SD) n=5398
Set up Preparation of booklets 
describing the scheme
£336 (0) £2.86 (0)
Design of intervention £96 (0) £0.82 (0)
Development of the 
website with information 
about the scheme—
including the postcode 
calculator
£64 (0) £0.55 (0)
Procurement of the 
vouchers from vendors 
(supermarkets and 
Love2shop)
£39 (0) £0.33 (0)
Initial local engagement £426 (371) £7.34 (9.17)
Advertisement £394 (0) £3.36 (0)
Training/Induction 
sessions for health visitors 
and midwives
£131 (70) £1.65 (1.22)
Delivery Vouchers £7453 (5028) £64.44 (18)
Processing time for claim 
forms
£317 (214) £2.74 (0.77)
Information packs 
(including the booklets 
describing the scheme)
£283 (148) £3 (1.46)
Delivery of letters to 
mothers
£189 (122) £2.10 (0.76)
Costs of telephone, texts 
for processing claims
£166 (0) £1.41 (0)
Processing time for 
applications to join the 
NOSH scheme
£93 (60) £0.84 (0.30)
Total cost £9989 (5538) £91.45 (22.38)
NOSH, Nourishing Start for Health.
Table 2 shows the regression-based estimates for costs, effects 
and incremental cost-effectiveness. Compared with control, 
the costs were higher for intervention wards (+£9738, 95% CI 
£8520 to £10 957). Online supplementary 2-3 show the regres-
sion-based estimates.
At baseline, area-level breastfeeding prevalence at 68 weeks 
was 27.4 (95% CI 25.2 to 29.6) in control and 28.7 (95% CI 
26.7 to 30.6) in the intervention areas. At follow-up (for 1 April 
2015 to 31 March 2016), area-level breastfeeding prevalence at 
68 weeks was 31.7% (95% CI 29.4 to 34.0) in control areas 
and 37.9% (95% CI 35.0 to 40.8) in intervention areas.7 The 
adjusted difference between intervention and control was 5.7 
percentage points (95% CI 2.7 to 8.6; p<0.001), resulting in 10 
(95% CI 6 to 14) more additional babies breast fed in the inter-
vention wards (39 vs 29). The cost per additional baby breast fed 
at 68 weeks was £974. Thus, at a cost per quality-adjusted life 
year (QALY threshold of £20 000 (recommended in England), 
an additional breastfed baby would need to show a lifetime total 
QALY gain to the infant and/or mother of 0.05 to justify the 
intervention cost. The required QALY gain decreases further to 
0.03 if the threshold is £30 000.
Deterministic sensitivity analyses (table 2) show that vouch-
er-only cost per additional baby breast fed at 68 weeks is 
£725 and £250 when only non-voucher costs are considered. 
Assuming the intervention is rolled out; the cost per additional 
baby breast fed will be £840. Probabilistic sensitivity analysis 
indicates that if decision makers WTP for additional breastfed 
baby is £1000, the intervention has 54% chance of being cost-ef-
fective (figure 1). At a WTP of £1500, the probability of inter-
vention being cost-effective increases to 94% and to 99% if the 
WTP is £2000.
DISCUSSION
During the 1-year trial, the total cost of offering financial incen-
tives for 5398 mother-infant dyads living in 46 areas with low 
breastfeeding prevalence was £462 600. Intervention areas 
compared with control required an additional cost (adjusted esti-
mates) of £9738 (95% CI £8520 to £10,957) per ward, equiv-
alent of £83 (95% CI £73 to £93) per baby. Compared with 
control areas, the intervention areas reported 10 more breastfed 
babies (95% CI 6 to 14) at 68 weeks per ward (39 vs 29). The 
mean cost per additional baby breast fed at 68 weeks was £974. 
There is a 54% chance of the scheme being considered cost-ef-
fective if decision makers were willing to pay £1000 per addi-
tional baby breast fed. Sensitivity analyses did not change this 
conclusion.
These findings feed into a sparse and mixed evidence base on 
cost-effectiveness of interventions to increase breast feeding.15 
One UK study reported that breastfeeding groups facilitated 
by a health professional led to higher costs (£5 per attendance) 
DQG D ORZHU EUHDVWIHHGLQJ UDWH DW ² ZHHNV ï16 Other 
studies showed that more intensive support and contact with 
health professionals offer good value for money with Rice et 
al17 showing such interventions are cheaper and more effec-
tive. Hoddinott et al18 compared the cost-effectiveness of team 
(proactive) and women-initiated (reactive) telephone support 
for breast feeding after discharge compared with reactive only 
and reported an incremental cost per additional woman breast-
feeding of £87.
This is the first study to examine the cost-effectiveness of a 
financial incentive for breastfeeding intervention. The data on 
cost and effectiveness were sourced from a cluster RCT with 
92% follow-up. The resource use data for costing were collected 
prospectively using mostly logging system and computer-based 
records. This method led to minimal errors with respect to ascer-
tainment of resource use and no missing data, a rarity in trial-
based economic evaluations.19
There are a number of limitations to this analysis. First, breast 
feeding has a wide range of benefits for both mothers and babies 
in both the short term and long term.1 This analysis did not 
account for data on health service use or utility estimates and 
this limits the comparison with non-breastfeeding programmes 
in the health sector. Second, the lack of data on the long-term 
benefits of breast feeding to both mother and child means that 
the value for money of the intervention is underestimated. Breast 
feeding has health benefits to both mothers and babies over the 
whole life course.1 Obtaining robust estimates of the life time 
costs and benefits of breast feeding to both the mother and baby 
is difficult due to the need to model outcomes far into the future, 
and was outside the scope of this analysis.
A 2012 comprehensive review by Renfrew et al found a clear 
association between increased breast feeding and reduced cases 
of necrotising entercolitis in preterm babies, acute otitis media, 
lower respiratory tract infections and gastrointestinal infec-
tions, which was of sufficient quality to allow the estimation of 
the economic impacts of improved breastfeeding rates.20 They 
showed that 45% of women exclusively breast feeding for 4 
months and 75% of babies in neonatal units being breast fed at 
discharge can lead to 3285 fewer gastrointestinal infection-re-
lated admissions and 10 637 fewer general practitioner (GP) 
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Table 2 Regression estimates for costs, effects and cost-effectiveness (pound sterling 2015–16)
Control (46 wards; 4612 mother-
infant dyads)
Intervention (46 wards; 5398 mother-
infant dyads)
Mean (95% CI) Mean (95% CI)
Base-case analysis
  Total cost per ward (£) £0 (0 to 0) £9738 (8520 to 10957)
  Incremental cost (£) –   £9738 (8520 to 10957)
  Percentage of babies breast fed at at 6–8 weeks per ward 31.7% (29.4 to 34.0) 37.9% (35.0 to 40.8)
  Total number of babies breast fed at 6–8 weeks per ward 29 (27 to 32) 39 (36 to 43)
  Incremental number of breastfed babies –   10 (6 to 14)
  Cost per additional baby breast fed at 6–8 weeks (£) –   £974
Deterministic sensitivity analyses
Assuming that the provision of vouchers is the only accruable to the intervention
  Total voucher cost per ward (£) £0 (0 to 0) £7251 (6117 to 8385)
  Incremental non voucher cost (£) –   £7251 (6117 to 8385)
  Total number of babies breast fed at 6–8 weeks per ward 29 (27 to 32) 39 (36 to 43)
  Incremental breast feeding –   10 (6 to 14)
  Voucher cost per additional baby breast fed at 6–8 weeks (£) –   £725
Assuming that the provision of vouchers will be free of charge to the providers
  Total non-voucher cost per ward (£) £0 (0 to 0) £2498 (2355 to 2638)
  Incremental non-voucher cost (£) –   £2498 (2355 to 2638)
  Total number of babies breast fed at 6–8 weeks per ward 29 (27 to 32) 39 (36 to 43)
  Incremental breast feeding –   10 (6 to 14)
  Non-voucher cost per additional baby breast fed at 6–8 weeks (£) –   £250
Cost of routinely rolling out intervention
  Total roll out cost per ward (£) £0 (0 to 0) £8402 (7154 to 9649)
  Incremental roll out cost (£) –   £8402 (7154 to 9649)
  Total number of babies breast fed at 6–8 weeks per ward 29 (27 to 32) 39 (36 to 43)
  Incremental breast feeding –   10 (6 to 14)
  Roll cost per additional baby breast fed at 6–8 weeks (£)     £840
Figure 1 Cost effectiveness acceptability curve showing probability of 
cost effectiveness at different Willing to Pay (pounds sterling) values
consultations (over £3.6 million treatment costs saving yearly); 
5916 fewer lower respiratory tract infection-related hospital 
admissions and 22 248 fewer GP consultations (over £6.7 million 
treatment cost saving yearly); 21 045 fewer acute otitis media-re-
lated general practice consultations (over £750 000 treatment 
cost saving yearly) and 361 fewer cases of necrotising entercolitis 
(over £6 million treatment cost saving yearly). The application 
of these cost savings to the NOSH data is, however, challenged 
by the specific diseases included within the cost estimates. For 
example, the estimate on necrotising entercolitis was based on 
preterm babies within the neonatal intensive care unit (ICU). 
It would be inappropriate to attribute this cost savings to the 
increase in breast feeding within the NOSH trial, as the interven-
tion was not targeted at mothers of preterm infants, and breast-
feeding rates within the ICU were not assessed within the trial.
However, although evidence supported an association 
between increased breast feeding and improved cognitive 
outcomes, reduced early obesity and reduced sudden infant death 
syndrome, the available literature was not of sufficient quality to 
allow estimation of the scale and scope of the risk reduction with 
precision. With respect to the association between breast feeding 
and other diseases such as asthma, diabetes and cardiovascular 
disease, the strength of the evidence was also deemed not suffi-
cient to allow estimation of the risk reduction and economic 
impact. Further well-designed studies are needed, which include 
adequate follow-up of outcomes, accurate definition and 
measurement of breast feeding and appropriate adjusting for 
confounding to inform the estimation of the long-term health 
and economic impacts of improved breast feeding.
With respect to quantifying how reasonable the 0.05 QALY 
gain over lifetime is (estimated to justify the intervention cost), 
with currently available data, this is difficult to do. The short-
term benefits on acute otitis media, lower respiratory tract infec-
tion and gastrointestinal infections are generally associated with 
mild sequelae within the UK and are of limited duration, thereby 
resulting in only small utility deficits.2024 On the other hand, 
some of the long-term sequelae, which do not have adequate data 
available currently to quantify accurately the relative risk reduc-
tion associated with breast feeding as listed above, would be asso-
ciated with greater QALY deficits; however, many occur later in 
life and therefore the benefits and costs would be reduced due to 
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discounting. Without an accurate estimate of the risk reduction 
associated with the increase in breast feeding achieved within 
the NOSH trial, it is not possible to model the impact on the 
incidence of long-term outcomes and consequently the poten-
tial QALY gain. Future studies are recommended to measure the 
short-term and long-term health impact of interventions.
Our analysis was based on the evidence from one trial, which 
tested a single permutation of the idea of offering financial 
incentives to mothers to breast feed. Future research is needed 
to help optimise this ideatesting a number of different varia-
tions. For example, would a universal single payment of £50 to 
mothers for exclusive breast feeding at 68 weeks be more or 
less effective in increasing breastfeeding rates? Additionally, the 
data on breast feeding were based on clinician reports collected 
as part of country-wide public health monitoring purposes. The 
validity of these reports are not usually assessed7 and therefore 
the use of objective measures of breastfeeding should be consid-
ered in future research.
This study provides information to help inform public health 
guidance on breast feeding. Implementing financial incentives 
to increase breast feeding in areas with low breastfeeding preva-
lence could offer value for money if policy makers are willing to 
pay £974 (or more) per additional baby breast fed. To make the 
economic case unequivocal, more research is required to provide 
effectiveness data on financial incentives for breast feeding 
beyond 68 weeks and epidemiological evidence on the varied 
health benefits of breast feeding to both the baby and mother. 
This will allow the incorporation of long-term health benefits of 
breast feeding in an economic analysis and facilitate the compar-
ison of financial incentives for breast feeding with a wide range 
of other public health programmes and healthcare technologies.
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